The DiscovEHR study, conducted by the Regeneron Genetics Center and the Geisinger Health System, uncovered many associations between genetic variants and clinical phenotypes.
The healthcare provider organizations are tasked with managing patient enrollment in the Precision Medicine Initiative.
The Pharmacogenomics Clinical Annotation Tool interprets variants from sequencing or genotyping tests and generates a report to inform prescribing decisions.
Geisinger Health System's MyCode Community Health Initiative has signed up more than 100,000 participants and has returned results to about 100 patients.
The decision was made after Geisinger researchers and clinicians presented the health plan with evidence of the clinical utility of exome sequencing.
Geisinger will use the funding to trial its GenomeFIRST Medicine program, which aims to integrate genetic results into standard patient care.
The Geisinger Health System team found 241 genes, including 17 new ones, which could be related to autism, schizophrenia, and other disorders.
Geisinger is returning actionable results from 76 genes in order to study how genomics can be integrated into a healthcare setting to guide patient management.
The research will focus on the genetic factors behind the variable phenotypes observed in patients with developmental brain disorders such as schizophrenia and autism.
Drug companies are rushing toward genomic databases to inform their searches for new drugs, Reuters reports.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.